BeiGene Announces The Phase 3 RATIONALE 315 Trial Met Primary Endpoints Of Major Pathological Response Rate And Event-Free Survival For Tislelizumab Plus Chemotherapy In Patients With Resectable Non-Small Cell Lung Cancer

百濟神州宣佈3期RASTIONAL 315試驗達到主要終點，即替雷利珠單抗加化療在可切除的非小細胞肺癌患者中的主要病理反應率和無事件存活率

Benzinga · 2023/10/18 04:05

Late-breaking ESMO data show 56.2% of patients with resectable NSCLC who received tislelizumab plus chemotherapy before surgery achieved major pathological response, versus 15.0% of those treated with neoadjuvant chemotherapy alone
Analysis also found 40.7% of patients on the tislelizumab-based regimen achieved the key secondary endpoint of pathological complete response, compared to 5.7% of patients who received neoadjuvant chemotherapy alone
In a subsequent interim analysis from RATIONALE 315, addition of tislelizumab to neoadjuvant platinum-based chemotherapy followed by adjuvant tislelizumab monotherapy demonstrated statistically significant improvement in event-free survival compared to neoadjuvant chemotherapy alone

最新的 ESMO 數據顯示，在手術前接受替雷利珠單抗聯合化療的可切除非小細胞肺癌患者中，有 56.2% 出現重大病理反應，而僅接受新輔助化療治療的患者中，這一比例爲 15.0%
分析還發現，使用替雷利珠單抗療法的患者中有40.7％達到了病理學完全反應的關鍵次要終點，而單獨接受新輔助化療的患者中，這一比例爲5.7％
在隨後的RASTIONAL 315中期分析中，與單獨使用新輔助化療相比，在新輔助鉑類化療中加入替雷利珠單抗後再進行替雷利珠單抗輔助單一療法顯示，與單獨使用新輔助化療相比，無事件存活率有統計學上的顯著改善

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

風險及免責聲明